OncoMatch/Clinical Trials/NCT06957431
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Is NCT06957431 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Zanzalintinib and Eribulin for advanced leiomyosarcoma.
Treatment: Zanzalintinib · Eribulin — The investigators hypothesize that the combination of eribulin and zanzalintinib will be tolerable and lead to improved progression-free survival (PFS) as compared to eribulin alone based on historical data.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: zanzalintinib (zanzalintinib)
Prior treatment with zanzalintinib
Cannot have received: small molecule kinase inhibitor
Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment
Cannot have received: cytotoxic, biologic, or other systemic anticancer therapy
Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment
Cannot have received: radiation therapy for bone metastasis
Radiation therapy for bone metastasis within 2 weeks before first dose of study treatment
Cannot have received: other radiation therapy
any other radiation therapy within 4 weeks before first dose of study treatment
Cannot have received: systemic treatment with radionuclides
Systemic treatment with radionuclides within 6 weeks before first dose of study treatment
Cannot have received: investigational agents
Currently receiving any other investigational agents
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 K/cumm without granulocyte colony-stimulating factor support within 2 weeks of collection; Platelets ≥ 100 K/cumm without transfusion within 2 weeks of collection; Hemoglobin ≥ 9.0 g/dL without transfusion within 2 weeks of collection
Kidney function
Serum creatine ≤ 1.5 x IULN or calculated creatinine clearance ≥ 40 mL/min by Cockcroft-Gault; UPCR ≤ 1 mg/mg (≤ 113.2 mg/mmol) creatinine
Liver function
Total bilirubin ≤ 1.5 x IULN (for subjects with Gilbert's disease, ≤ 3.0 x IULN); AST(SGOT)/ALT(SGPT)/alkaline phosphatase (ALP) ≤ 3.0 x IULN (for subjects with documented bone metastasis, ALP ≤ 5.0 x IULN); Serum albumin ≥ 2.8 g/dL
Cardiac function
INR ≤ 1.5 x ULN and aPTT ≤ 1.2 x ULN; for subjects on Factor Xa inhibitors, this criterion does not apply. Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 480 ms within 14 days per ECG before first dose of study treatment
Adequate bone marrow and organ function within 14 days before first dose of study treatment as defined below: Absolute neutrophil count ≥ 1.5 K/cumm without granulocyte colony-stimulating factor support within 2 weeks of collection; Platelets ≥ 100 K/cumm without transfusion within 2 weeks of collection; Hemoglobin ≥ 9.0 g/dL without transfusion within 2 weeks of collection; INR ≤ 1.5 x ULN and aPTT ≤ 1.2 x ULN; for subjects on Factor Xa inhibitors, this criterion does not apply. Total bilirubin ≤ 1.5 x IULN (for subjects with Gilbert's disease, ≤ 3.0 x IULN); AST(SGOT)/ALT(SGPT)/alkaline phosphatase (ALP) ≤ 3.0 x IULN (for subjects with documented bone metastasis, ALP ≤ 5.0 x IULN); Serum albumin ≥ 2.8 g/dL; Serum creatine ≤ 1.5 x IULN or calculated creatinine clearance ≥ 40 mL/min by Cockcroft-Gault; UPCR ≤ 1 mg/mg (≤ 113.2 mg/mmol) creatinine; Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 480 ms within 14 days per ECG before first dose of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify